Recent research trials surrounding the medication Retatrutide , specifically the 120 milligram formulation referred to as ZPHC, suggest a considerable effect on weight decrease and linked metabolic illnesses . Experts believe that this innovative acting , targeting both GLP-1 and GIP receptors , has the potential to represent a substantial advance